Omeros also has identified MASP-3 as the protein that is critical to the activation of the complement system’s alternative pathway in humans, which is linked to a wide range of immune-related ...

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced publication of study results showing that inhibition of mannan-binding lectin-associated serine protease-2 (MASP-2) protects ...

SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (Nasdaq: OMER) today announced publication of study results showing that inhibition of mannan-binding lectin-associated serine protease-2 (MASP-2) ...

Please provide your email address to receive an email when new articles are posted on . Kim’s hypothesis arises partially from studies that showed that C3, when introduced to synthetic neutrophils, ...

Dianthus achieved its NASDAQ listing last year via a merger with Magenta Therapeutics. The company is focused on development of a single drug candidate, DNTH-103, which targets the complement system, ...

Iron nanoparticles injected before magnetic resonance imaging can make tissues more visible and the same nanoparticles may allow doctors to precisely target tumors with new medicines. However, among ...

(RTTNews) - Omeros Corp. (OMER), a clinical-stage biopharmaceutical company focused on complement-mediated diseases, oncology, and addictive disorders, today announced its financial results for the ...

Please provide your email address to receive an email when new articles are posted on . A protein known as granzyme K was recently shown to be a driver of inflammation by activating the complement ...